Actively Recruiting

Phase 2
Age: 16Years +
All Genders
NCT06379360

Maintenance Therapy of Hypomethylating Agent (HMA) in Favorable Risk Acute Myeloid Leukemia (AML) Patients

Led by The First Affiliated Hospital of Soochow University · Updated on 2026-03-19

77

Participants Needed

1

Research Sites

426 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

HMA maintenance therapy is expected to benefit overall survival (OS) and relapse free survival (RFS) in AML patients with favorable risk.

CONDITIONS

Official Title

Maintenance Therapy of Hypomethylating Agent (HMA) in Favorable Risk Acute Myeloid Leukemia (AML) Patients

Who Can Participate

Age: 16Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients aged 63;16 years
  • Diagnosed with acute myeloid leukemia (AML) in the favorable-risk group according to European LeukemiaNet 2022
  • Achieved remission after induction therapy and completed at least 3 cycles of high-dose Aar-C based consolidation therapy, remaining in minimal residual disease (MRD) negative remission status
  • No prior hematopoietic stem cell transplantation
  • Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2
  • Expected survival time of at least 3 months
  • No serious heart, lung, liver, or kidney disease
  • Ability to understand and willing to sign informed consent form for the trial
Not Eligible

You will not qualify if you...

  • Experienced hematologic relapse before recruitment
  • Allergy to study drug or similar chemical structures
  • Pregnant or lactating women, or women of childbearing age not using effective contraception
  • Active infection
  • Active bleeding
  • New thrombosis, embolism, cerebral hemorrhage, or related medical history within one year before enrollment
  • Mental disorders or inability to provide informed consent or comply with study procedures
  • Liver function abnormalities or renal anomalies exceeding specified limits
  • History of significant heart conditions including QTc prolongation, ventricular tachycardia, atrial fibrillation, heart block, recent myocardial infarction, congestive heart failure, or symptomatic coronary heart disease
  • Surgery on main organs within the past six weeks
  • Drug abuse or long-term alcohol abuse affecting evaluation
  • History of organ transplants except bone marrow transplantation
  • Assessed as unsuitable for the study by the investigator

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

The First Affiliated Hospital of Soochow University

Suzhou, Jiangsu, China, 215006

Actively Recruiting

Loading map...

Research Team

S

Sheng-Li Xue, M.D.

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here